JANE RYAN, PH.D.

Corporate Board Profile

Tech Score: 0/100

← Back to All Directors

Neuphoria Therapeutics Inc.

Filing Date Source Excerpt
2024-11-12 Jane Ryan, Ph.D. Includes 400,000 shares that Dr. Ryan has the right to acquire pursuant to options that are exercisable as of October 31, 2024, or will become exercisable within 60 days of such date.

Source material: SEC submissions metadata and DEF 14A proxy filings from EDGAR. Last updated: 2026-03-22